Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 + D-1553 in KRAS G12C-mutated advanced solid tumors
ChiCTR2600124637Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GH21 and garsorasib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Safety and tolerability (Phase Ib), Dose-limiting toxicity incidence (Phase Ib) and 1 more. Started May 2026; status: recruiting.
02
Drugs
GH21garsorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600124637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124637.